New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
08:50 EDTKPTIKaryopharm submits NADA for Verdinexor to FDA CVM
Karyopharm Therapeutics announced that it has submitted to the FDA Center for Veterinary Medicine, or CVM, the effectiveness and safety technical sections under a New Animal Drug Application, or NADA, for Verdinexor for the treatment of dogs with newly diagnosed or first relapsed non-Hodgkin lymphoma, or NHL. Verdinexor has received a designation from the CVM's Office of Minor Use and Minor Species, or MUMS, for the treatment of companion dogs with lymphoma, and the required portions of the NADA are being submitted initially under the CVM's MUMS guidelines.
News For KPTI From The Last 14 Days
Check below for free stories on KPTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
16:08 EDTKPTIKaryopharm announces initiation of Phase 1 study of Selinexor-decitabine combo
Karyopharm Therapeutics announced the initiation of a Phase 1 combination trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor in combination with the DNA methylation inhibitor decitabine in patients with relapsed or refractory acute myeloid leukemia, or AML, and in patients age 60 years with newly diagnosed AML. Sharon Shacham, Karyopharm's founder, President and Chief Scientific Officer, commented, "This first combination study of Selinexor represents a significant milestone for the company as we look to broaden the scope of SINE compounds in the treatment of cancers."
April 9, 2014
10:02 EDTKPTIKaryopharm enters into preferred provider agreement with Clinipace Worldwide
Clinipace Worldwide announced that Karyopharm Therapeutics has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases. As part of a long-term strategic partnership, Clinipace expects to manage numerous study starts on behalf of Karyopharm in 2014.
April 7, 2014
17:11 EDTKPTIKaryopharm requests withdrawal of registration statement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use